Amyloidosis treatment has changed more in the last five years than in the previous fifty, but it's still organized around three genuinely different diseases that happen to share a name. What's approved, what's being tested, and even how research gets designed all depend heavily on which type someone has. This piece looks specifically at where each type's research stands, including the most technically ambitious idea in the field: editing the gene responsible in a single dose.
Looking for treatment options for amyloidosis?
Browse open Amyloidosis clinical trials near you! We'll handle the follow-up.
What's approved right now, in plain terms, by type
For ATTR amyloidosis: tafamidis and acoramidis work by stabilizing the misfolded protein so it's less likely to clump together. Vutrisiran and patisiran work upstream of that, they reduce how much of the problem protein the body makes in the first place, by targeting the genetic instructions for it in liver cells. Vutrisiran is currently the only one approved for both the heart and nerve forms of ATTR.
For AL amyloidosis: daratumumab, already a well established multiple myeloma drug, is combined with three chemotherapy-style drugs to reduce the abnormal plasma cells producing the harmful protein in the first place. This is the only currently approved option built specifically for newly diagnosed AL amyloidosis.
For AA amyloidosis: there's no dedicated approved drug. Treatment focuses on controlling whatever inflammatory disease is driving it, since the amyloid buildup tends to slow once the underlying inflammation is controlled.
What researchers are studying now
The most striking idea in amyloidosis research right now is editing a gene directly. A treatment called NTLA-2001, made by Intellia Therapeutics and Regeneron, uses CRISPR to edit the TTR gene inside liver cells, the gene responsible for making the harmful protein in the first place. It's given as a single IV infusion. In early trials, the treatment cut TTR protein levels by roughly 90% at the higher dose after just one year.
Because it changes the DNA itself instead of just blocking the protein temporarily, researchers are hopeful that one dose could mean lasting benefit, maybe even for life. It's also a bigger deal than just amyloidosis: this is the first time CRISPR has ever been used to edit genes inside a living person's body, for any disease. That's part of why it's drawn so much attention. It's still investigational and not available outside of a trial.
Researchers are also exploring a different approach: antibodies designed to clear out amyloid deposits that have already built up in organs, rather than just stopping new ones from forming. This work is earlier stage, but it's being tested for both AL and ATTR amyloidosis.
Why amyloidosis research is unusually hard
The three-diseases-one-name problem. A therapy built for ATTR's protein-stabilization mechanism does nothing for AL amyloidosis, which comes from an entirely different source. Every new approach has to be tested, essentially from scratch, in each type separately.
The diagnosis-lag problem. Because early amyloidosis symptoms, fatigue, mild swelling, vague shortness of breath, overlap heavily with far more common conditions like heart failure, many patients see several specialists before anyone considers amyloidosis specifically. By the time a trial-eligible diagnosis is confirmed, some organ damage may have already progressed further than it would have with earlier detection, which shapes which patients trials can realistically enroll and what outcomes they can measure.
The permanence question. Gene editing approaches like NTLA-2001 raise a genuinely new research question the field hasn't had to answer before: if an edit is effectively permanent, how long does a trial need to run to be confident about safety, and how do you design a trial around a treatment that, unlike a daily pill, can't simply be stopped if something unexpected shows up later.
Does amyloidosis research connect to other diseases?
Yes, directly. AL amyloidosis is closely tied to multiple myeloma, since both start with the same abnormal plasma cell process, and drugs developed for one condition sometimes get tested in the other, daratumumab being the clearest example. This kind of cross-disease drug reuse is one reason rare disease research sometimes moves faster than people expect: a therapy doesn't always have to start from zero.
Common myths, cleared up
"Amyloidosis is one disease with one cause."
It's genuinely three different diseases (AL, ATTR, AA) that happen to share the word amyloidosis because they all involve misfolded protein deposits, not because they share a cause.
"If it's not cancer, it's not really that serious."
AL amyloidosis in particular is treated by hematologists using cancer-adjacent drugs and monitoring, because its underlying cause, abnormal plasma cells, is closely related to blood cancer biology, even though amyloidosis itself isn't classified as cancer.
"Gene editing means it's basically cured already."
NTLA-2001 and similar approaches are still investigational, with relatively short follow-up so far. Early reductions in the harmful protein are promising, but long-term safety and durability data are still being gathered.
How to find an amyloidosis study through our platform
Since amyloidosis research really splits by type, that's the best place to start your search, then narrow by which organs are affected for you. Right now, for example, you can find a Phase 1 study testing JNJ-79635322, a drug being tested in both relapsed multiple myeloma and AL amyloidosis at once, the same cross-disease pattern described above, and a study using cardiac imaging to track acoramidis in people with ATTR-CM. Our amyloidosis clinical trials page always shows the full, current list of what's recruiting. Applying takes about 5 minutes, and a coordinator follows up to confirm fit based on your specific type.
Common questions
What are the symptoms of amyloidosis? Symptoms depend heavily on which organs are affected, but common ones include fatigue, swelling in the legs or abdomen, shortness of breath, numbness or tingling in the hands and feet, and unexplained weight loss. Because these overlap with so many other conditions, symptoms alone rarely lead straight to a diagnosis.
How is amyloidosis actually diagnosed? A biopsy that shows amyloid deposits under a microscope is what confirms the general diagnosis. From there, additional tests, blood work, genetic testing, or a specialized heart scan, determine which specific type is present, which matters enormously for treatment.
Is amyloidosis genetic? It depends on the type. ATTR amyloidosis can be hereditary, caused by a specific change in the TTR gene, and genetic testing is sometimes offered to family members of someone diagnosed. AL and AA amyloidosis aren't passed down through genes in the same way.
Is there a cure for amyloidosis? Not yet, for any type. Current treatments slow the disease, reduce the harmful protein, or in the case of gene editing research, aim at the source directly, but none reverse organ damage that's already happened.
Is CRISPR gene editing available for amyloidosis patients now? No, NTLA-2001 remains investigational and is only available by joining a clinical trial. It has not been submitted for approval as of this writing.